NFKB1 and cardiac hypertrophy: It has been shown that LILRB4 prevents pathological cardiac hypertrophy through SHP-2-dependent inhibition of the NF-κB pathway, and it may serve as a potential therapeutic target for cardiac hypertrophy [141].